Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2020 02:00 ET | Source: Epigenomics AG

New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening

Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and...
December 02, 2019 08:30 ET | Source: Epigenomics AG

Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the...
November 29, 2019 09:00 ET | Source: Epigenomics AG

New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer

- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the...
July 24, 2019 08:30 ET | Source: Epigenomics AG

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

BERLIN, July 24, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary...
July 11, 2019 08:30 ET | Source: Epigenomics AG

Epigenomics AG Receives MedTech Outlook's 2019 Top 10 In-Vitro Diagnostics Award

- Company recognized for its leadership in advancing blood-based tests to diagnose cancer - BERLIN and SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX,...
June 17, 2019 08:00 ET | Source: Epigenomics AG

New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

- Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the...
May 19, 2019 12:30 ET | Source: Epigenomics AG

New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test

– Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests – BERLIN and SAN DIEGO, May 19, 2019 (GLOBE NEWSWIRE) -- Epigenomics...
January 22, 2009 01:14 ET | Source: Epigenomics AG

Sysmex and Epigenomics AG Announce Strategic R&D Collaboration in Colorectal Cancer Diagnostics

- Focus on Detection of Methylated DNA in Blood Using Sysmex Instrumentation - Sysmex Assay System to be Benchmarked Against Epigenomics' mSEPT9 Assay - Parties Entered Into...
January 22, 2009 01:11 ET | Source: Epigenomics AG

Ad hoc: Epigenomics AG: Ad hoc Announcement According to Section 15 WpHG (German Securities Trading Act): Epigenomics AG Signs Strategic R&D Collaboration Agreement in Colorectal Cancer with Sysmex Corporation

BERLIN, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN: DE000A0BVT96) today signed a strategic research and development collaboration agreement in molecular diagnostics with...
December 19, 2008 07:22 ET | Source: Epigenomics AG

Ad hoc: Epigenomics AG: Ad hoc Announcement According to Section 15 WpHG (German Securities Trading Act): Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based Cancer Diagnostics

BERLIN, Germany, Dec. 19, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt:ECX) (ISIN:DE000A0BVT96) and Royal Philips Electronics (NYSE:PHG) (AEX:PHI) today entered into a...